Consolidated net profit after tax recorded EGP270.76 million during the six-month period ended June 30th, compared to profit of EGP 262.20 million in H1 2020.
Meanwhile, standalone net profit after tax rose by 10% YoY to EGP 244.99 million from EGP 221.76 million.
Last Sunday, EIPICO announced it achieved sales of EGP 1.54 billion in H1 of 2021.
EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
Get Zawya's daily newsletter for insightful and exclusive Middle East perspectives on business and finance. SUBSCRIBE NOW